This content is for healthcare professionals outside of the UK only.

This activity is funded by an independent medical education grant from Seagen Inc. and Genmab US, Inc. and is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Downloads
    Download Slides
    Download Fact Sheet
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Aline Chaves

    DOM Oncology Group, Divinópolis, Brazil

    Dr Aline Chaves is a medical oncologist and director of the DOM Oncology Group in Divinópolis, Brazil.

    Dr Chaves is founder and director of the Brazilian Group of Head and Neck Cancer and co-chair of the Latin American Cooperative Oncology Group (LACOG) – Head and Neck.

    Dr Aline Chaves discloses: Advisory board or panel fees from Knight, Merck Serono and MSD. Speaker’s Bureau fees from Eli Lilly, Knight, Merck Serono and MSD.
    Prof. Makoto Tahara

    National Cancer Center Hospital East, Kashiwa, Japan

    Prof. Makoto Tahara is chief of the Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. read more

    Prof. Tahara has a strong interest in the development of novel treatments for head and neck cancer, including thyroid cancer, and has been a principal investigator on six investigator-initiated clinical studies. He has been a steering committee member for 15 global clinical studies. Additionally, Prof. Tahara was a group manager of the Head and Neck Cancer Group in the Japanese Clinical Oncology Group (JCOG) from 2012 to 2016. 

    Prof. Tahara has served as a reviewer or member of the editorial board for five international journals, and has authored or co-authored more than 150 international scientific papers.

    Prof. Makoto Tahara discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Lilly, Merck Biopharma, MSD and Pfizer. Consultant fees from Astellas, Genmab and Janssen Pharmaceuticals. Grants/Research Support from Bayer and Ono Pharmaceutical.

    Dr Ranee Mehra

    Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA

    Dr Ranee Mehra is director of Head and Neck Medical Oncology, head of the Solid Tumor Section and professor in the Department of Medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

    Dr Mehra is a clinical investigator with a focus on the treatment of head and neck and thoracic cancers. Her research interests also include incorporation of biomarkers in clinical trial design and developmental therapeutics.

    Dr Mehra is a member of the American Society of Clinical Oncology (ASCO) and the Eastern Cooperative Oncology Group (ECOG) Head and Neck Core Committee. She is also a member of the National Cancer Institute (NCI) Head and Neck Recurrent/Metastatic Task Force.

    Dr Ranee Mehra discloses: Advisory board or panel fees from Coherus, EMD Serono/Merck and Janssen (relationships terminated). Grants/Research Support from Merck.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    SEE ALL VIDEOS
    Start activity

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which investigational immunotherapy combinations do you think are most promising?

    Submit your answer to see the results

    Immune checkpoint inhibitor (ICI) + LAG3 inhibitor
       
    ICI + bispecific antibody
       
    ICI + tyrosine kinase inhibitor
       
    Triplet combinations
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which targeted therapy do you think will have the biggest impact on future practice?

    Submit your answer to see the results

    VEGF inhibitors
       
    Antibody-drug conjugates
       
    HRAS inhibitors
       
    PI3K inhibitors
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    In your opinion, what are the main challenges when treating patients with R/M SCCHN?

    Submit your answer to see the results

    Limited treatment options
       
    Managing side effects
       
    Lack of biomarkers
       
    Other
       
     
    Expert Interviews
    Head and Neck Cancer, Immunotherapy CE/CME accredited

    touchEXPERT OPINIONS
    Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

    What’s on the horizon to tackle unmet needs in recurrent/metastatic SCCHN?

    Take CE/CME Test

    Dr Aline Chaves is a medical oncologist and director of the DOM Oncology Group in Divinópolis, Brazil.

    Dr Chaves is founder and director of the Brazilian Group of Head and Neck Cancer and co-chair of the Latin American Cooperative Oncology Group (LACOG) – Head and Neck.

    Dr Aline Chaves discloses: Advisory board or panel fees from Knight, Merck Serono and MSD. Speaker’s Bureau fees from Eli Lilly, Knight, Merck Serono and MSD.

    Take CE/CME Test

    Prof. Makoto Tahara is chief of the Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. read more

    Prof. Tahara has a strong interest in the development of novel treatments for head and neck cancer, including thyroid cancer, and has been a principal investigator on six investigator-initiated clinical studies. He has been a steering committee member for 15 global clinical studies. Additionally, Prof. Tahara was a group manager of the Head and Neck Cancer Group in the Japanese Clinical Oncology Group (JCOG) from 2012 to 2016. 

    Prof. Tahara has served as a reviewer or member of the editorial board for five international journals, and has authored or co-authored more than 150 international scientific papers.

    Prof. Makoto Tahara discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Lilly, Merck Biopharma, MSD and Pfizer. Consultant fees from Astellas, Genmab and Janssen Pharmaceuticals. Grants/Research Support from Bayer and Ono Pharmaceutical.

    Take CE/CME Test

    Dr Ranee Mehra is director of Head and Neck Medical Oncology, head of the Solid Tumor Section and professor in the Department of Medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

    Dr Mehra is a clinical investigator with a focus on the treatment of head and neck and thoracic cancers. Her research interests also include incorporation of biomarkers in clinical trial design and developmental therapeutics.

    Dr Mehra is a member of the American Society of Clinical Oncology (ASCO) and the Eastern Cooperative Oncology Group (ECOG) Head and Neck Core Committee. She is also a member of the National Cancer Institute (NCI) Head and Neck Recurrent/Metastatic Task Force.

    Dr Ranee Mehra discloses: Advisory board or panel fees from Coherus, EMD Serono/Merck and Janssen (relationships terminated). Grants/Research Support from Merck.

    Take CE/CME Test
    Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Recall unmet treatment needs for patients with recurrent/metastatic SCCHN
    • Discuss the rationale and latest data for immunotherapy-based treatments in development for recurrent/metastatic SCCHN
    • Evaluate the rationale and latest data for investigational targeted therapies for recurrent/metastatic SCCHN
    Overview

    In this activity, oncologists specializing in the treatment of head and neck cancer consider the current unmet treatment needs for patients with recurrent/metastatic SCCHN and provide an update on treatment approaches under investigation, including the available clinical trial data.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of oncologists involved in the management of patients with head and neck cancer.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr Aline Chaves discloses: Advisory board or panel fees from Knight, Merck Serono and MSD. Speaker’s Bureau fees from Eli Lilly, Knight, Merck Serono and MSD.

    Prof. Makoto Tahara discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Lilly, Merck Biopharma, MSD and Pfizer. Consultant fees from Astellas, Genmab and Janssen Pharmaceuticals. Grants/Research Support from Bayer and Ono Pharmaceutical.

    Dr Ranee Mehra discloses: Advisory board or panel fees from Coherus, EMD Serono/Merck and Janssen (relationships terminated). Grants/Research Support from Merck.

    Content Reviewer

    Danielle Walker, DNP, APRN, AGNP-C has no relevant financial relationships to disclose.

    Touch Medical Contributors

    Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.

    Amelia Campbell-Warner discloses: Employee or independent contractor relationship – Astellas and Ipsen (relationships terminated).

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 29 February 2024. Date credits expire: 01 March 2025.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchMDT

    Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    New Checkpoint Inhibitors and Immunotherapies for Solid Tumours

    GO TO ARTICLE

    CONFERENCE HUB

    Ian Chau, ASCO 2021: First Results of the Phase III CheckMate 648 Trial

    GO TO HUB

    CONFERENCE HUB

    Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer

    GO TO HUB

    touchEXPERT OPINIONS

    What’s on the horizon for the treatment of solid tumours in 2019?

    LAUNCH ACTIVITY

    JOURNALS

    Immune Checkpoint Inhibition for Triple-negative Breast Cancer

    GO TO ARTICLE

    Topics covered in this activity

    Head and Neck Cancer / Immunotherapy
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from Seagen Inc. and Genmab US, Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside of the UK only.

    Date of original release: 29 February 2024. Date credits expire: 01 March 2025.

    Claim Credit
    touchEXPERT OPINIONS
    What’s on the horizon to tackle unmet needs in recurrent/metastatic SCCHN?
    0.75 CE/CME credit
    Question 1/5
    Which of the following statements is true regarding the response rates associated with first-line pembrolizumab for recurrent or metastatic SCCHN in the KEYNOTE-048 trial after 4 years of follow-up?

    CPS, combined positive score; ORR, objective response rate; PD-L1, programmed death-ligand 1; SCCHN, squamous cell carcinoma of the head and neck.

    After 4 years of follow-up in the KEYNOTE-048 trial, the ORR with pembrolizumab alone was 23.3% in patients with PD-L1 CPS ≥20, 19.1% in patients with PD-L1 CPS ≥1, and 16.9% in the total population. The ORR with pembrolizumab plus chemotherapy was 43.7% in patients with PD-L1 CPS ≥20, 37.2% in patients with PD-L1 CPS ≥1, and 36.3% in the total population.

    Abbreviations

    CPS, combined positive score; ORR, objective response rate; PD-L1, programmed death-ligand 1.

    Reference

    Harrington KJ, et al. J Clin Oncol. 2023;41:790–802.

    Question 2/5
    Which of the following statements best summarizes the latest data for investigational or novel immunotherapy-based combinations for recurrent/metastatic SCCHN?

    ChT, chemotherapy; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCCHN, squamous cell carcinoma of the head and neck; TKI, tyrosine kinase inhibitor.

    Multiple studies have demonstrated consistent and promising results with PD-1/PD-L1 inhibitors plus cetuximab.1 The combination of PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel demonstrated anti-tumour activity and tolerable toxicity profiles in patients with R/M SCCHN.2,3 There are a number of PD-1/PD-L1 inhibitors in combination with TKIs under investigation for R/M SCCHN that have shown variable antitumour activity with manageable toxicity profiles.4–7 However, multiple studies did not meet their primary endpoint (OS/ORR) when assessing the efficacy of CTLA-4 inhibition in combination with anti-PD-1/PD-L1 monoclonal antibodies compared to standard-of-care regimens.8–11  

    Abbreviations

    CTLA-4, cytotoxic T-lymphocyte associated protein 4; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; R/M SCCHN, recurrent or metastatic squamous cell carcinoma of the head and neck; TKI, tyrosine kinase inhibitor.

    References

    1. Wise-Draper TM, et al. Am Soc Clin Oncol Educ Book. 2022;42:1–14; 2. Dzienis MR, et al. Ann Oncol. 2022;33(Suppl. 7):S839–40; 3. Fayette J, et al. J Clin Oncol. 2023;41(Suppl. 16):Abstr 6003; 4. Rottey S, et al. J Immunother Cancer. 2022;10(Suppl. 2):A597; 5. Gui L, et al. Ann Oncol. 2022;33(Suppl. 9):S1524; 6. Kao HF, et al. Clin Cancer Res. 2022;128:1560–71; 7. Licitra L, et al. Presented at: Multidisciplinary Head and Neck Cancers Symposium 2024, Phoenix, AZ, USA. 29 February–2 March 2024. Abstract; 8. Ferris RL, et al. Ann Oncol. 2020;31:942–50; 9. Psyrri A, et al. Ann Oncol. 2023;34:262–74; 10. Harrington KJ, et al. JAMA Oncol. 2023;9:779–89; 11. Haddad RI, et al. J Clin Oncol. 2022;41:2166–80.

    Question 3/5
    Your patient with metastatic SCCHN is entering a clinical trial investigating eftilagimod alpha, a LAG-3-targeting agent, plus pembrolizumab. They ask you what outcomes have been reported from prior trials. What do you tell them regarding the ORR from the TACTI-002 trial?

    LAG-3, lymphocyte activation gene 3; ORR, objective response rate; SCCHN, squamous cell carcinoma of the head and neck.

    In the phase II TACTI-002 trial investigating eftilagimod alpha plus pembrolizumab in the second-line setting, an ORR of 30% was reported in 37 patients.

    Abbreviation

    ORR, objective response rate.

    Reference

    Doger de Spéville BD, et al. J Clin Oncol. 2023;41(Suppl. 16):6029.

    Question 4/5
    Which of the following is a target of bevacizumab, an agent currently under investigation for the treatment of recurrent or metastatic SCCHN?

    EGFR, epidermal growth factor receptor; LAG-3, lymphocyte activation gene 3; PI3K, phosphatidylinositol 3-kinase; SCCHN, squamous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor.

    Bevacizumab is a humanized anti-VEGF monoclonal antibody approved for the treatment of various cancer types and is currently under investigation for R/M SCCHN. Although bevacizumab is not approved for SCCHN, clinical trials of bevacizumab have shown its effectiveness and tolerability in improving the outcomes of patients with R/M SCCHN. The VEGF pathway is a promising therapeutic target in SCCHN; however, further studies should focus on minimizing unwanted adverse effects, especially bleeding events.

    Abbreviations

    R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor. 

    Reference

    Li Q, et al. Signal Transduct Target Ther. 2023;8:31.

    Question 5/5
    In what range was the reported ORR in the innovaTV 207 trial evaluating tisotumab vedotin monotherapy in patients with recurrent/metastatic SCCHN who have received prior lines of therapy, including platinum therapy?

    ORR, objective response rate; SCCHN, squamous cell carcinoma of the head and neck.

    The phase II innovaTV 207 study evaluated the efficacy of tisotumab vedotin in patients with R/M SCCHN (n=15). The ORR was reported as 40%. 

    Abbreviations

    ORR, objective response rate; R/M SCCHN, recurrent or metastatic squamous cell carcinoma of the head and neck. 

    Reference

    Cirauqui B, et al. Cancer Res. 2023;83 (Suppl. 8):CT164.

    Back to Activity

    You may also be interested in...

    touchEXPERT OPINIONS

    Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchEXPERT OPINIONS

    Guideline-based treatment of recurrent/metastatic cervical cancer

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial

    GO TO HUB

    CONFERENCE HUB

    Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer

    GO TO HUB

    JOURNALS

    Bevacizumab Therapy for Choroidal Melanoma

    GO TO ARTICLE

    JOURNALS

    Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from Seagen Inc. and Genmab US, Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside of the UK only.

    Date of original release: 29 February 2024. Date credits expire: 01 March 2025.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup